BioSpace News Archive

Amid troubling reports of significant drops in plasma donations, John G. Boyle, President & CEO of The Immune Deficiency Foundation, a national organization for people affected by primary immunodeficiency, addressed the looming plasma shortage at the IDF 2020 National Summit, a virtual event held over the weekend focused on the PI community on a national level.

Transgene present new data on BT-001, a novel oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment, in the SITC abstract “BT-001, an oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment”.

AMV564, a novel first-in-class agent that depletes MDSC and activates T cells, is being investigated in a Phase 1 clinical trial in advanced solid tumors

HIV Pioneer and world-renowned scientist to advise NeuroCytonix as it develops technology to improve the lives of patients suffering from neurological disorders

The American Association of Kidney Patients, the nation’s largest independent kidney patient organization and a global champion for patient care choice and treatment innovation, unveiled their inaugural President’s Volunteer Service Awards program by recognizing exceptional volunteers for their ongoing advocacy and response to the COVID-19 pandemic.

Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, announced the FDA approval of Gemmily™, 1 mg/20 mcg, a therapeutically equivalent generic version of Taytulla®.

Seven and Eight Biopharmaceuticals Inc. announced interim Phase 1 results evaluating BDB001, its Toll-like receptor 7/8 agonist, at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting to be held virtually November 9 – 14, 2020.

For the third year, on Oct. 26, SMU Cox Caruth Institute for Entrepreneurship named Intuitive Health- the national leader in dual ER and Urgent Care models-to its coveted list of Dallas 100 companies.

74% of patients treated with CLARIX® FLO demonstrated clinically significant improvement at 12 months, signifying its potential in delaying Total Knee Arthroplasty (TKA)

FINTEPLA® (fenfluramine) oral solution launched in the U.S. in late July for Dravet syndrome with high enrollment of physicians and patients into the FINTEPLA Risk Evaluation and Mitigation Strategy (REMS) program